Results 101 to 110 of about 4,836 (184)

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real‐world study

Risankizumab efficacy and safety in psoriatic patients with latent tuberculosis infection: A multicentric real-world ...
Ligrone, Luigi, Musumeci, ML, Amerio, Paolo, Uzzauto, Maria Teresa, Amerio, P, Uzzauto, MT, Guarneri, Claudio, Puca, RV, Lembo, Serena, Fargnoli, MC, Balato, A, Puca, Rosa Valentina, Musumeci, Maria Letizia, Balato, Anna, Guarneri, C, Raimondo, A, Cusano, Francesco, Cusano, F, Fargnoli, Maria Concetta, Megna, Matteo, Lembo, S, Raimondo, Annunziata, Megna, M, Ligrone, L   +23 more
core   +1 more source

Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn’s Disease: A Real-World Retrospective Cohort Study from Taiwan

Journal of Inflammation Research
Ming-Jung Meng,1– 6 Shih-Hua Lin,8 Chien-Ming Chen,3,5,9 Tai-Di Chen,3,7,10 Chia-Jung Kuo,1– 5 Tony Kou,1,3,5 Cheng-Tang Chiu,1– 5 Puo-Hsien Le1– 61Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan; 2Taiwan ...
Meng MJ, Lin SH, Chen CM, Chen TD, Kuo CJ, Kou T, Chiu CT, Le PH   +7 more
doaj  

Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)

Background The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psoriasis.
Luca Potestio, Cameli, Norma, Claudio Bonifati, Orsini, Diego, Assorgi, Chiara, Dario Graceffa, Bonifati, Claudio, Potestio, Luca, Matteo Megna, Norma Cameli, Diego Orsini, Megna, Matteo, Chiara Assorgi, Graceffa, Dario   +13 more
core   +1 more source

Severe Hypertriglyceridemia Associated With Acute Pancreatitis in a Patient on Risankizumab. [PDF]

ACG Case Rep J
El Yazal S, Chokshi A, Hudhud D.
europepmc   +1 more source

Risankizumab in Psoriasis: Real-World Effectiveness, Safety, and Clinical Outcomes. [PDF]

Clin Cosmet Investig Dermatol
Alkofide M, Madani A, Alsukait S, Alotaibi H, Almaqbali HS, Alshehri NA, Barakeh M, Alharbi BA, Nagshabandi KN.   +8 more
europepmc   +1 more source

Real-World Experience of Risankizumab in Refractory Pediatric Inflammatory Bowel Disease. [PDF]

ACG Case Rep J
Alsarhan A, Krishnamurthy B, Elyyan E, Alhajjar M, Tzivinikos C.   +4 more
europepmc   +1 more source

Potential association between IL-12/23, IL-23, and IL-17 inhibitors and skin cancer: a pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Jiang X, Huang Y, Xie M, Peng L, Xu M, Qi Z, Wang G, Pu X.   +7 more
europepmc   +1 more source

Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study. [PDF]

Antibodies (Basel)
Balestri R, Pallanch C, Magnano M, Colombini J, Clarizio G, Bardazzi F, Di Lernia V, Satolli F, Ganzetti G, Buligan C, Mazzoletti V, Pacetti L, Odorici G, Borghi A, Saraceno R, Mengarino M, Gisondi P, Girolomoni G, Lacava R, Rech G, Bellinato F.   +20 more
europepmc   +1 more source

Outcomes of risankizumab use in adults with Crohn's disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study. [PDF]

BMJ Open Gastroenterol
Butler TD, Beard A, Ososanya A, Parr E, Kwok J, Fekadu H, Chater F, Kakosa V, Morgan J, Bonnar C, Kemp K, Nixon E, Kneebone A, Kuriakose Kuzhiyanjal A, Ormerod C, Knight PP, Shuttleworth E, Butcher R, Chatten K, Crooks B, Limdi JK, White K.   +21 more
europepmc   +1 more source

Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry. [PDF]

Inflamm Bowel Dis
Verleye LMM, Pierik MJ, de Vries AC, van Schaik FDM, van der Meulen-de Jong AE, van Dop WA, Löwenberg M, Visschedijk MC, Naber MR, Bouwknegt DG, Römkens TEH, Bodelier AGL, Voorneveld PW, Oldenburg B, Derikx LAAP, Duijvestein M, Mujagić Z, Dutch Initiative on Crohn and Colitis (ICC) .   +17 more
europepmc   +1 more source